Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manmath Patekar

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical and Translational Science|July 13, 2026
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous UrticariaYan Ji, Claudio Calonder, Tiina Kirsiläe, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 23, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous UrticariaAndrzej Bienczak, Aurelie Gautier, Eva Hua, et al.
British Journal of Clinical Pharmacology|October 29, 2019
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patientsGerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, et al.
Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Pharmaceutics|September 28, 2023
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery SystemYan Ji, Claudio Calonder, Tiina Kirsilä, et al.
Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Modern Rheumatology|March 24, 2026
Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in JapanTatsuya Atsumi, Yohei Kirino, Mitsumasa Kishimoto, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical and Translational Science|July 13, 2026
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous UrticariaYan Ji, Claudio Calonder, Tiina Kirsiläe, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 23, 2025
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous UrticariaAndrzej Bienczak, Aurelie Gautier, Eva Hua, et al.
British Journal of Clinical Pharmacology|October 29, 2019
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patientsGerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, et al.
Paediatric Drugs|June 13, 2022
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized StudyNina Magnolo, Külli Kingo, Vivian Laquer, et al.
Pharmaceutics|September 28, 2023
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery SystemYan Ji, Claudio Calonder, Tiina Kirsilä, et al.
Journal of the American Academy of Dermatology|September 23, 2021
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week resultsNina Magnolo, Külli Kingo, Vivian Laquer, et al.
The Journal of Dermatological Treatment|April 26, 2021
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE studyBardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, et al.
The British Journal of Dermatology|January 4, 2022
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trialMatthias Augustin, Kristian Reich, Paul Yamauchi, et al.
Dermatology and Therapy|October 19, 2018
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)Jerry Bagel, John Nia, Peter W Hashim, et al.
Modern Rheumatology|March 24, 2026
Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in JapanTatsuya Atsumi, Yohei Kirino, Mitsumasa Kishimoto, et al.
Pageof 2